T. Rowe Price Investment Management
SRPT icon

T. Rowe Price Investment Management’s Sarepta Therapeutics SRPT Stock Holding History

T. Rowe Price Investment Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.8M Buy
1,156,083
+22,775
+2% +$431K 0.01% 543
2026
Q1 		$24.7M Buy
1,133,308
+241,243
+27% +$4.67M 0.02% 443
2025
Q4 		$19.2M Sell
892,065
-474,625
-35% -$10M 0.01% 503
2025
Q3 		$26.3M Buy
1,366,690
+891,932
+188% +$15.9M 0.02% 474
2025
Q2 		$8.12M Sell
474,758
-1,523,233
-76% -$65M 0.01% 568
2025
Q1 		$128M Buy
1,997,991
+41,408
+2% +$4.36M 0.08% 233
2024
Q4 		$238M Buy
1,956,583
+10,343
+0.5% +$1.27M 0.15% 155
2024
Q3 		$243M Sell
1,946,240
-12,395
-0.6% -$1.71M 0.15% 163
2024
Q2 		$309M Buy
1,958,635
+27,088
+1% +$3.48M 0.2% 124
2024
Q1 		$250M Buy
1,931,547
+11,805
+0.6% +$1.45M 0.15% 161
2023
Q4 		$185M Buy
1,919,742
+24,422
+1% +$2.34M 0.12% 196
2023
Q3 		$230M Buy
+1,895,320
New +$214M 0.16% 157

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

T. Rowe Price Investment Management's SRPT Position: Q2 2026 in Review

T. Rowe Price Investment Management increased its Sarepta Therapeutics (SRPT) stake by 2% in Q2 2026, buying an estimated $431K and bringing the position to 1,156,083 shares worth $20.8M. The position accounts for 0.01% of the portfolio, ranked #543.

T. Rowe Price Investment Management first reported a position in SRPT in Q3 2023 and has held it in 12 quarters since. The position peaked at $309M in Q2 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • T. Rowe Price Investment Management held 1,156,083 shares of Sarepta Therapeutics worth $20.8M as of Q2 2026.
  • T. Rowe Price Investment Management bought 22,775 Sarepta Therapeutics shares in Q2 2026, an estimated $431K.
  • Sarepta Therapeutics made up 0.01% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #543 holding.
  • T. Rowe Price Investment Management first reported a position in Sarepta Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • T. Rowe Price Investment Management's Sarepta Therapeutics position peaked at $309M in Q2 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.